Anti-vascular endothelial growth factors (anti-VEGF) have become the most common
treatment modality for many retinal diseases. These include neovascular age-related …

Subthreshold micropulse laser treatment has been intensively used for selected retinal
diseases in the last decade; however, the exact mechanism of the action of lasers in the …

Purpose To examine the effect of delay in care on visual acuity (VA) in patients requiring
intravitreal injections (IVIs). Design Retrospective cohort study. Participants Patients 18 …

Purpose Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers
excellent visual acuity gains with strong durability in patients with diabetic macular edema …

Purpose The non-interventional OCEAN study (NCT02194803) evaluated frequency and
monitoring of ranibizumab injections for retinal vein occlusion (RVO) in routine practice in …

Purpose To determine the correlation between aqueous humor cytokine levels and the
prognostic value of anti-vascular endothelial growth factor (VEGF) therapy for treating …

Retinal degenerative diseases are a leading cause of vision loss and blindness throughout
the world, characterized by chronic and progressive loss of neurons and/or myelin. One of …

There are~ 463 million diabetics worldwide, and more than half have diabetic retinopathy.
Yet, treatments are still lacking for non-proliferative diabetic retinopathy. We and others …

Diabetic retinopathy is a diabetes-mediated retinal microvascular disease that is the leading
cause of blindness in the working-age population worldwide. Interleukin (IL)-17A is an …

Purpose To evaluate the 24-week efficacy and safety of the dual angiopoietin-2 (Ang-2) and
vascular endothelial growth factor (VEGF)-A inhibitor faricimab versus aflibercept in patients …